Welcome to our dedicated page for IceCure Medical Ltd. SEC filings (Ticker: ICCM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
IceCure Medical Ltd. filings document the company’s status as a foreign private issuer and its disclosures around ProSense cryoablation technology, clinical and regulatory updates, commercial activity, governance and capital structure. Form 6-K reports furnish press releases on financial and operating results, FDA-related matters, medical-conference updates and clinical data for ProSense in tumor-destruction applications.
The filing record also includes proxy materials for shareholder voting, registration-statement references on Forms F-3 and S-8, ordinary-share voting information, executive and board changes, employment and indemnification arrangements, and litigation disclosure related to a prior private placement. These filings frame ICCM’s formal reporting around its medical-device business and public-company obligations.
IceCure Medical Ltd. filed an initial ownership report for Chief Executive Officer Eyal Shamir, detailing his existing equity position. As of March 18, 2026, he directly holds 791,381 ordinary shares, plus a range of vested and unvested equity awards.
Footnotes show additional exposure through restricted share units granted on May 15, 2025; November 5, 2025; and March 16, 2026, with portions vesting in 25% cliffs and 6.25% quarterly installments thereafter. Shamir also holds multiple fully or partially vested share options over ordinary shares with exercise prices converted from Israeli shekels into U.S. dollars, including options over 117,551 shares at an exercise price of $0.82 per share expiring January 23, 2027, and several later grants expiring between 2028 and 2033. The filing records these as holdings only, with no reported recent purchases, sales, or option exercises.
IceCure Medical reported positive 5‑year top-line results from its ICESECRET study of the ProSense® cryoablation system in kidney cancer. At a median follow-up of four years, 83.9% of the 112 evaluated patients with small renal masses were recurrence-free based on imaging.
In a subgroup with tumors ≤3 cm, no prior kidney cancer and successful initial procedures, the recurrence-free rate reached 89.4%. The trial enrolled 114 patients across two centers in Israel, and full data are expected to be presented at the European Conference on Interventional Oncology 2026 in Basel.
IceCure Medical appointed Meir Peleg as Chief Financial Officer, with his employment beginning on May 17, 2026, under an employment agreement and standard indemnification terms used for its directors and executives. He brings over 20 years of financial leadership, including experience as a Nasdaq-listed company CFO.
The company reported the resignation of its Vice President of R&D and Engineering, Naum Muchnik, effective April 12, 2026. IceCure also plans to appoint breast surgical oncologist Dr. Richard E. Fine as Medical Director in the second quarter of 2026, supporting breast cryoablation clinical and educational initiatives.
IceCure Medical Ltd. filed an amendment to its Form F-3 shelf registration to register up to $100,000,000 of Ordinary Shares, warrants or units, to be offered from time to time after the effective date hereof. The prospectus supplements will state the specific offering terms, prices and proceeds treatment for each sale.
The prospectus notes 73,122,293 Ordinary Shares issued and outstanding as of December 31, 2025, cash and cash equivalents of $8,897,000 as of that date, and lists issuable securities including options, RSUs and warrants from the Rights Offering.
IceCure Medical Ltd. files a post-effective amendment to permit issuance of up to 9,744,072 ordinary shares upon exercise of outstanding warrants and pre-funded warrants.
The shares comprise warrants exercisable at $1.00 and pre-funded warrants exercisable at $0.0001. If fully exercised, the company expects to receive net proceeds of approximately $9.7 million. The prospectus states 73,180,045 Ordinary Shares outstanding as of March 20, 2026 and an as‑adjusted post‑exercise share count shown in the offering materials. The amendment updates the prospectus and covers issuance of Ordinary Shares underlying unexercised warrants; no additional securities are being registered.
IceCure Medical Ltd. reported that Mr. Li Haixiang resigned from its Board of Directors, effective March 17, 2026. The company stated that his resignation was not related to any disagreement regarding its operations, policies, or practices. This report is also incorporated by reference into several existing IceCure Medical registration statements on Forms F-3 and S-8.
IceCure Medical reported record 2025 sales of about $3.4M, up slightly from $3.3M, driven by growing global adoption of its ProSense® cryoablation system after FDA clearance for low-risk breast cancer. Management highlights added support from recent ASBrS medical society recommendations and rising interest from hospitals and clinics.
GAAP revenue was $3.379M, with gross profit of $1.226M and gross margin falling to 36% from 44% a year earlier as costs rose. Operating expenses declined to $16.32M, mainly from lower sales and marketing costs, while R&D and G&A increased.
Net loss narrowed slightly to $15.057M, or $0.24 per share, compared with $15.318M, or $0.30 per share. Cash and cash equivalents, including short-term deposits, grew to $8.897M as of December 31, 2025, helped by $15.539M in net proceeds from share and warrant issuances and additional warrant exercises.
IceCure Medical Ltd. files its annual report on Form 20‑F, outlining a commercial‑stage medical device business focused on minimally invasive cryoablation systems to treat tumors in the breast, lungs, kidneys, bones and other indications.
The company’s lead ProSense system received FDA De Novo marketing authorization for local treatment of low‑risk breast cancer in women aged 70 and above, and its next‑generation XSense system has 510(k) clearance. As of December 31, 2025, IceCure reports accumulated losses of $120,436 thousand, a 2025 net loss of about $15,057 thousand, negative operating cash flow of $14,574 thousand, and cash and deposits of approximately $8.9 million. Management and the auditor highlight conditions that raise substantial doubt about the company’s ability to continue as a going concern, and IceCure expects it will need substantial additional funding while facing intense competition, supply‑chain risks, regulatory hurdles, reimbursement uncertainty and extensive clinical and post‑market obligations.